SBTX vs. HVO, TILS, VSN, FUM, MPH, SCLP, ORPH, REDX, ETX, and TRX
Should you be buying SkinBioTherapeutics stock or one of its competitors? The main competitors of SkinBioTherapeutics include hVIVO (HVO), Tiziana Life Sciences (TILS), Verseon (VSN), Futura Medical (FUM), Mereo BioPharma Group plc (MPH.L) (MPH), Scancell (SCLP), Open Orphan (ORPH), Redx Pharma (REDX), e-therapeutics (ETX), and Tissue Regenix Group (TRX). These companies are all part of the "biotechnology" industry.
SkinBioTherapeutics vs.
SkinBioTherapeutics (LON:SBTX) and hVIVO (LON:HVO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, valuation, analyst recommendations, media sentiment, earnings, profitability, risk and dividends.
In the previous week, hVIVO had 1 more articles in the media than SkinBioTherapeutics. MarketBeat recorded 1 mentions for hVIVO and 0 mentions for SkinBioTherapeutics. hVIVO's average media sentiment score of 0.37 beat SkinBioTherapeutics' score of 0.00 indicating that hVIVO is being referred to more favorably in the news media.
16.6% of SkinBioTherapeutics shares are held by institutional investors. Comparatively, 34.9% of hVIVO shares are held by institutional investors. 20.4% of SkinBioTherapeutics shares are held by company insiders. Comparatively, 14.0% of hVIVO shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
SkinBioTherapeutics has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500. Comparatively, hVIVO has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.
hVIVO has higher revenue and earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than hVIVO, indicating that it is currently the more affordable of the two stocks.
hVIVO received 76 more outperform votes than SkinBioTherapeutics when rated by MarketBeat users. Likewise, 69.89% of users gave hVIVO an outperform vote while only 60.26% of users gave SkinBioTherapeutics an outperform vote.
hVIVO has a net margin of 25.96% compared to SkinBioTherapeutics' net margin of 0.00%. hVIVO's return on equity of 58.04% beat SkinBioTherapeutics' return on equity.
Summary
hVIVO beats SkinBioTherapeutics on 12 of the 15 factors compared between the two stocks.
Get SkinBioTherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for SBTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SkinBioTherapeutics Competitors List
Related Companies and Tools
This page (LON:SBTX) was last updated on 1/21/2025 by MarketBeat.com Staff
Free SBTX Stock Alerts